Exit events / 859
#859
| id | 859 |
|---|---|
| company_id | 11051 |
| event_type | acquisition |
| event_date | 2026-07-14 |
| counterparty_company_id | 15960 |
| successor_company_id | — |
| deal_value_usd | 739000000.0 |
| deal_value_basis | reported |
| notes | Completed acquisition ([subscription] Ligand Pharmaceuticals completed its acquisition of XOMA Royalty Corp. on July 14, 2026, at $39 per... |
| source_urls | ["https://links.message.bloomberg.com/s/c/lH-UB0HPrvslq8OVfB_4HEjUZ7I2pxjHloRPjqAHJiwRz8knbDTu1tSjIvt9qKgkj3SY4uR19K9Nsi8WzEQVHOSQ0dwgVBQ... |
| payload | {"signal_id"=>4596, "deal_status"=>"completed", "subject_role"=>"target"} |
| entered_by_person_id | — |
| entered_at | 2026-10-04T16:10:09.478885+00:00 |
| data_source | email_signal:19fa896364d29fcc |
| data_confidence | reported |